her2-mutant
Entity, reached from Hormuz.
- Evidence
- 16 documents · 4 separate publishers
- Standing
- Added automatically from coverage
- Time
- first seen 10 Sept 2026, last seen 6 Oct 2026
- Measured
- 25% of mentions say something specific about it; the rest only name it
- As of
- 10 Oct 2026
Where this comes from
- Frontiers Precision Oncology · 2026-09-25 · Small cell transformation during acquired resistance to zongertinib in HER2-mutant non-small cell lung cancer: a case report (opens the source in a new tab)
- The ASCO Post · 2026-09-22 · Metastatic HER2-Mutant NSCLC First-Line T-DXd (opens the source in a new tab)
- The ASCO Post · 2026-09-17 · First-Line Trastuzumab Deruxtecan Prolongs PFS in HER2-Mutant NSCLC (opens the source in a new tab)
- Fierce Pharma · 2026-09-10 · FDA clears Bayer’s Hyrnuo in first-line lung cancer, amping up Hernexeos rivalry (opens the source in a new tab)
What is claimed about it
Situations it is named in
Who it moves with
- co-mentioned with her2 (16 documents)seen together
- co-mentioned with lung cancer (16 documents)seen together
- co-mentioned with her2-directed (13 documents)seen together
- co-mentioned with egfr-mutated (11 documents)seen together
- co-mentioned with t-dxd (11 documents)seen together
- co-mentioned with wclc (11 documents)seen together
- co-mentioned with cancer center (10 documents)seen together
- co-mentioned with dana-farber cancer institute (10 documents)seen together
- co-mentioned with iaslc (10 documents)seen together
- co-mentioned with iiia (8 documents)seen together